文献速递浆细胞疾病造血干细胞移植与细胞治疗

新诊断多发性骨髓瘤患者接受自体干细胞移植后单药来那度胺维持治疗:MD安德森经验

Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience.
PubMed 文献 · Am J Hematol · 2023-07-17

该回顾性单中心分析纳入2005至2021年间接受自体造血干细胞移植后单药来那度胺维持治疗的1167例多发性骨髓瘤患者,中位随访47.9个月,中位无进展生存期和总生存期分别为56.6个月和111.3个月;更长的维持治疗持续时间与更优的生存相关,但超过2年后第二原发恶性肿瘤风险升高。

要点

  • 中位无进展生存期56.6个月,中位总生存期111.3个月
  • 维持治疗时间更长与无进展生存期和总生存期改善相关
  • 维持治疗超过2年后第二原发恶性肿瘤风险升高

核心结论

  • 来那度胺维持治疗的结局与大型临床试验报告的结果相当。
  • 更长的维持治疗持续时间,甚至超过5年,与生存改善相关。

研究设计与样本

  • 回顾性单中心分析,纳入2005年至2021年间接受 upfront 自体造血干细胞移植后单药来那度胺维持治疗的成年多发性骨髓瘤患者,共1167例。

主要发现

  • 中位年龄61.4岁(范围25.4-82.3),高危染色体异常占19%。
  • 中位维持治疗持续时间22.3个月(范围0.03-139.6)。
  • 中位随访47.9个月(范围2.9-171.7),全队列中位无进展生存期56.6个月(95%CI 48.2-61.4),中位总生存期111.3个月(95%CI 101.7-121.5)。
  • 多变量分析中,高危细胞遗传学与更差的无进展生存期(HR 1.91)和总生存期(HR 1.73)相关(两者p<.001)。
  • 采用KRD诱导和移植前达到MRD阴性≥VGPR与无进展生存期改善相关(HR分别为0.53和0.57;两者p<.001)。

局限性

  • 回顾性单中心分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The optimal duration of lenalidomide (Len) maintenance for patients with multiple myeloma (MM) after autologous stem cell transplantation (autoHCT) is unknown. We conducted a retrospective single-center analysis of adult MM patients that received upfront autoHCT between 2005 and 2021, followed by single-agent Len maintenance. A total of 1167 patients were included with a median age of 61.4 (range 25.4-82.3) years, and high-risk chromosomal abnormalities in 19%. Median duration of maintenance was 22.3 (range 0.03-139.6) months. After a median follow-up of 47.9 (range 2.9-171.7) months, median PFS and OS for the entire cohort were 56.6 (95% CI 48.2-61.4) months and 111.3 (95% CI 101.7-121.5) months, respectively. In MVA, high-risk cytogenetics was associated with a worse PFS (HR 1.91) and OS (HR 1.73) (p < .001 for both). Use of KRD induction and achievement of MRD-negative ≥ VGPR before autoHCT were associated with an improved PFS (HR 0.53 and HR 0.57, respectively; p < .001 for both). Longer maintenance duration, even with a 5-year cutoff, was associated with superior PFS and OS (HR 0.17 and 0.12, respectively; p < .001 for both). A total of 106 patients (9%) developed a second primary malignancy (SPM), mostly solid tumors (39%) and myeloid malignancies (30%). Longer maintenance duration was associated with a higher risk of SPM, reaching statistical significance after >2 years (odds ratio 2.25; p < .001). In conclusion, outcomes with Len maintenance were comparable to those reported in large clinical trials. Longer duration of maintenance, even beyond 5 years, was associated with improved survival.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Pasvolsky O, Milton DR, Masood A, et al. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol. 2023. PMID: 37461327. doi:10.1002/ajh.27029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。